Navigation Links
Medicare Cuts May Have Spurred Drop in Prostate Cancer Treatment

FRIDAY, Dec. 3 (HealthDay News) -- Use of androgen suppression therapy for low-risk prostate cancer fell after doctors starting receiving lower Medicare payments for the treatment, but use of the treatment for patients with metastatic prostate cancer stayed steady, a new study shows.

The findings, published online Dec. 3 in the Journal of the National Cancer Institute, suggest the payment cuts may have reduced over-treatment of low-risk prostate cancer, the researchers said.

Between 1991 and 1999, the use of the therapy for prostate cancer increased more than threefold among patients with metastatic prostate cancer (cancer that has spread) and low-risk prostate cancer, even though the treatment has not been shown to improve survival in patients with low-risk disease.

When Medicare physician reimbursements for androgen therapy were reduced by 64 percent between 2004 and 2005, use of the therapy for men with low-risk prostate cancer fell by 40 percent while there was no statistically significant change among men with metastatic prostate cancer, the study found.

The researchers looked at factors other than Medicare payment cuts that could account for the findings, such as growing awareness of the therapy's side effects and increasing use of longer-acting treatments.

However, they concluded that the decline in use of androgen therapy for low-risk prostate cancer patients "likely represents a real effect of reimbursement change and not physician awareness of clinical evidence," wrote Dr. Sean P. Elliott, of the University of Minnesota, and colleagues in a news release from the journal.

More information

The American Urological Association has more about hormone therapy for prostate cancer.

-- Robert Preidt

SOURCE: Journal of the National Cancer Institute, news release, Dec. 3, 2010

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Internists issue heartfelt plea for Congress to help patients by stopping Medicare SGR cuts
2. Medicare Panel Endorses Vaccine for Prostate Cancer Patients
3. Medicare Part D Changes Not Overwhelming, Experts Say
4. Study shows drop in unnecessary care after Medicare reimbursement cut
5. Use of Prostate Cancer Treatment Fell When Medicare Paid Docs Less
6. Study identifies flaws in Medicare prescription drug program
7. Investment in CRC screening targeting pre-medicare population could cut medicare treatment costs
8. New Medicare model guidelines for benefit years 2012-2014 in development
9. Drug coverage under Medicare leads to increased use of antibiotics
10. Regional variation in health-care spending and utilization higher in Medicare than private sector
11. Study: Medicare policy may account for growing length of hospice stays in nursing homes
Post Your Comments:
Related Image:
Medicare Cuts May Have Spurred Drop in Prostate Cancer Treatment
(Date:12/1/2015)... ... ... ClinicoEconomics and Outcomes Research has published the ... ”. , As corresponding author Dr Ankita Modi says “Pre-existing gastrointestinal events may ... a large US managed care database, women aged 55 years or older with ...
(Date:12/1/2015)... ... December 01, 2015 , ... Physicians’ Education Resource®, ... (CME), today announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will ... detection and treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Growth in ... part due to decreases in utilization of hospital and nonhospital care, according to a ... CompScope™ Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... medical images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the ... North America Annual Meeting from November 29 to December 4, 2015. , ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage ... (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced ... Radiological Society of North America (RSNA) 2015 annual meeting through December 3 in ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
(Date:12/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced that it has reached its enrollment ... Phase 3 clinical trial of aldoxorubicin in patients with ... to be completed in Q1 2016. The Phase 3 trial ... Special Protocol Assessment from the FDA at 79 sites ...
Breaking Medicine Technology: